The 2022 Tandem Meetings | Chronic kidney disease in survivors of pediatric alloHSCT

Christine Duncan • 24 Apr 2022

The 2022 Tandem Meetings

General

Christine Duncan, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the findings of a retrospective study investigating renal toxicity following allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with hematological malignancies. The study found that a significant number of patients suffered from chronic kidney disease following transplantation, suggesting that it may be useful to monitor pediatric patients for kidney function. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.